Key Takeaways & Executive Findings
- •• This correction addresses two errors in the original article: a sentence on page 3 and a Y-axis label in Fig. 2C. • The correction clarifies the interpretation of B1 and B2 as indicating complete data, removing the ambiguous '(Ref)'. • The Y-axis label in Fig. 2C is corrected to 'Change in total motor score', removing the word 'lower'. • These corrections ensure accurate reporting of the clinical trial results on allogenic-Muse cell therapy for cervical spinal cord injury.
Abstract
The original article contains two errors which the authors wish to address: 1. On line 3 of page 3, the sentence should simply read, 'B1 and B2, which indicates complete […]', and the word '(Ref)' should be disregarded. 2. In Fig. 2C, the Y-axis label should instead read as 'Change in total motor score', and the word 'lower' should be disregarded.
1. Introduction
This article is a correction notice for the original publication titled 'Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial' by Koda et al. The correction addresses two errors identified in the original article.
The first error is on line 3 of page 3, where the sentence should read 'B1 and B2, which indicates complete […]' and the word '(Ref)' should be disregarded. The second error is in Fig. 2C, where the Y-axis label should read 'Change in total motor score' instead of the previous label that included the word 'lower'.
These corrections are important for the accurate interpretation of the study's findings and ensure that the data presented are correctly understood by readers.
Loading authentic research manuscript (Pages 1–5)...
Masao Koda, Shiro Imagama, Hiroaki Nakashima, Sadayuki Ito, Naoki Segi, Jun Ouchida, Kota Suda, Satoko Harmon Matsumoto, Miki Komatsu, Toshiki Endo, Shinsuke Suzuki, Satoshi Inami, Haruki Ueda, Masayuki Miyagi, Gen Inoue, Masashi Takaso, Keiji Nagata, Hiroshi Yamada, Naosuke Kamei, Toshio Nakamae, Hidenori Suzuki, Norihiro Nishida, Masahiro Funaba, Gentaro Kumagai, Takeo Furuya, Yu Yamato, Toru Funayama, Hiroshi Takahashi, Masashi Yamazaki (2026). Correction: Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-024-04044-0
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the purpose of this correction?
This correction addresses two errors in the original article to ensure accurate reporting of the study's findings.
What are the specific errors corrected?
The errors are: 1) a sentence on page 3 that incorrectly included '(Ref)', and 2) the Y-axis label in Fig. 2C that incorrectly included the word 'lower'.
How does this correction affect the interpretation of the results?
The correction clarifies that B1 and B2 indicate complete data, and the Y-axis label now correctly reads 'Change in total motor score', which may affect how readers interpret the motor score changes.
Who are the authors of the original article?
The authors are Masao Koda and colleagues from various institutions in Japan.
Where can I find the original article?
The original article can be found at https://doi.org/10.1186/s13287-024-03842-w.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.